T
Turn Therapeutics
Biotech & Life Sciences · Calabasas, United States · Founded 2015 · IPO 2025
Advanced wound care solutions reducing antibiotic resistance with innovative, clinically-backed products MoreLess
Turn Therapeutics is a pharmaceutical and medical device company focused on reducing the human and economic costs of infection and skin disease. The company operates in the healthcare market, specifically targeting acute and chronic wound care. Turn Therapeutics serves healthcare providers, hospitals, and clinics that require advanced wound care solutions. The business model revolves around the development and commercialization of innovative therapeutic candidates that are backed by clinical evidence and real-world feedback. Revenue is generated through the sale of these advanced wound care products and medical devices. The company's flagship technology, PermaFusion, is a liquid in oil suspension that enhances the effectiveness of topical treatments while minimizing risks such as toxicity and irritation. By using less active ingredient without compromising efficacy, Turn Therapeutics aims to reduce antibiotic resistance and improve patient outcomes. The company is committed to continuous innovation and education to make diseases obsolete.
Keywords: wound care, antibiotic resistance, PermaFusion, healthcare, medical devices, pharmaceutical, clinical evidence, innovation, topical delivery, skin disease.
Company overview
Turn Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Calabasas, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 87.0
Valuation & funding
Turn Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Mar 2026 | $7M | — | Avenue Capital Group | ↗ |
| IPOOther financing | Oct 2025 | $0 | — | Undisclosed | ↗ |
| GROWTH EQUITY VCOther financing | Dec 2024 | $75M | — | Global Emerging Markets | ↗ |
| EARLY VCOther financing | May 2024 | $24K | $123M | StartEngine | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$1.7M | — |
| 2025 | $0 | — | −$1.7M | — |
| 2024 | $0 | — | −$1.7M | — |
| 2023 | $0 | — | −$2.3M | — |
| 2022 | — | — | — | — |
| 2021 | — | — | — | — |
Growth signals
Turn Therapeutics website traffic
Latest recorded traffic for Turn Therapeutics is 7.5K monthly website visits, down 46.4% over the last three months. Turn Therapeutics's team grew 0% over the past year.
Comparisons
Turn Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Turn Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Turn Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Turn Therapeutics has talent and traffic
team presence
In the news
Latest news about Turn Therapeutics
Recent press, funding announcements, and product moves mentioning Turn Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Turn Therapeutics
An AI-synthesized read of the highest-engagement posts about Turn Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Turn Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.